QRL-101

DRUG5 trials

Sponsors

QurAlis Corporation

Conditions

Amyotrophic Lateral SclerosisHealthy Participant StudyHealthy Volunteers

Phase 1

A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

CompletedNCT05667779

QurAlis CorporationHealthy Volunteers

Start: 2022-12-22End: 2023-12-27Updated: 2024-04-15

A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy Participants

CompletedNCT06532396

QurAlis CorporationHealthy Volunteers

Start: 2024-07-01End: 2024-12-20Updated: 2025-02-14

A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS

CompletedNCT06714396

QurAlis CorporationAmyotrophic Lateral Sclerosis

Start: 2024-11-11End: 2025-08-22Updated: 2025-09-02

A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants

CompletedNCT06877624

QurAlis CorporationHealthy Volunteers

Start: 2025-01-10End: 2025-05-15Updated: 2025-08-26

A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants

Active, not recruitingNCT07421778

QurAlis CorporationHealthy Participant Study

Start: 2026-02-02End: 2026-08-31Target: 48Updated: 2026-08-11